Q10250: N. Ludwig, et al. Novel TGFbeta Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the
Antitumor Immune Response of Anti-PD-L1 Immunotherapy. Molecular Cancer Therapeutics 2021;20(6):1102-1111
Agents: Transforming growth factor beta-2 Vehicle: Not Stated; Route: SC; Species: Mice; Pump: 2004; Duration: 4 weeks;
ALZET Comments: Dose: (10 ug per day); animal info: female, immunocompetent C57BL/6J mice ages 8 weeks; Transforming
growth factor-b aka (TGFb); cancer (Oral squamous cell carcinoma);
Q10236: Y. Li, et al. Tacrolimus inhibits oral carcinogenesis through cell cycle control. Biomedicine & Pharmacotherapy
2021;139(111545
Agents: Tacrolimus Vehicle: Not Stated; Route: Not Stated; Species: Rat; Pump: Not Stated; Duration: 4 weeks;
ALZET Comments: Dose: (5 mg/kg/d); Controls received mp w/ vehicle; animal info: Male Sprague-Dawley (SD) rats (6–8
weeks old); Tacrolimus aka (TAC, FK506) is a major calcineurin inhibitor; cancer ();